GREAT POINT PARTNERS LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Vistagen Therapeutics, Inc. Common Stock, $0.001 par value per share (VTGN)

Filing Manager
GREAT POINT PARTNERS LLC
Reporting Manager
Great Point Partners, LLC
Security
Vistagen Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
VTGN
Shares outstanding
41,532,000 shares
Disclosed Ownership
2,055,834 shares
Ownership
5%
Form type
SCHEDULE 13G/A
Filing time
17 Feb 2026, 16:16:18 UTC
Date of event
31 Dec 2025
Previous filing
14 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"GREAT POINT PARTNERS LLC disclosed 5% ownership in Vistagen Therapeutics, Inc. Common Stock, $0.001 par value per share (VTGN) on 31 Dec 2025."

Quick Takeaways

  • GREAT POINT PARTNERS LLC filed SCHEDULE 13G/A for Vistagen Therapeutics, Inc. Common Stock, $0.001 par value per share (VTGN).
  • Disclosed ownership: 5%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 14 Nov 2025.
  • Current filing was accepted on 17 Feb 2026, 16:16.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Great Point Partners, LLC 5% 2,055,834 0 2,055,834 /s/ Dr. Jeffrey R. Jay, M.D Dr. Jeffrey R. Jay, M.D - Senior Managing Member
Dr. Jeffrey R. Jay, M.D. 5% 2,055,834 0 2,055,834 /s/ Dr. Jeffrey R. Jay, M.D Dr. Jeffrey R. Jay, M.D
Ms. Lillian Nordahl 5% 2,055,834 0 2,055,834 /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl

Sponsored